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Abstract: We report here an unprecedented and highly 
enantioselective palladium-catalyzed allylic alkylation applied to 
4-substituted isoxazolidin-5-ones. Ultimately, the process provides a 
straightforward access to β2,2-amino acids bearing an all-carbon 
quaternary stereogenic center in great yields and a high degree of 
enantioselectivity. 
Asymmetric methods allowing a straightforward access to β-
amino acids have been the focus of tremendous efforts ever 
since this structural motif was shown to offer interesting 
prospects in medicinal chemistry. Indeed, compounds bearing a 
β-amino acid moiety tend to exhibit remarkable biological 
activities along with increased biological stability, particularly 
towards common peptidases.[1] They have thus emerged as 
potent protease resistant peptidomimetics as well as potential 
precursors to β- or α/β-peptides and β-lactams.[2-4] Another 
important aspect of β-amino acids is their ability to fold into 
different secondary structures often with a reversed orientation 
of their α-amino acid counterparts. Interestingly however, 
despite all the methods that have been reported to access 
enantioenriched β2- and β3-amino acids,[5,6] the asymmetric 
synthesis of β2,2-amino acids remains a challenge,[7-8] in 
particular for compounds bearing a stereodefined all-carbon 
quaternary stereogenic centers (Figure 1A).[9]  
For the past several years, our group has focused on the 
development of new synthetic tools and strategically 
implementing them in the total synthesis of various biologically 
relevant natural products.[10] In this context, we recently applied 
the palladium-catalyzed asymmetric allylic alkylation[11] to two 
new classes of pro-chiral substrates, namely allyl dienol[12,13] and 
allyl enol[14] carbonates. This method provided a highly 
enantioselective access to a wide variety of chiral butenolides 
and butyrolactones bearing an all carbon α-quaternary 
stereogenic center. It was also used as a key step in the total 
synthesis of (−)-nephrosteranic acid and (−)-roccellaric acid, two 
members of the paraconic acid family of natural products,[15] 
which exhibit interesting antibiotic properties. In view of these  
 
Figure 1. A) Traditional synthetic routes to β2,2-amino acids. B) Palladium-
catalyzed asymmetric allylic alkylation of α-substituted isoxazolidin-5-ones. 
results, we envisioned that a Pd-AAA could potentially be 
applied to 4-substituted isoxazolidin-5-ones to afford the 
corresponding α,α-disubstituted products which could in turn be 
readily converted to β2,2-amino acids after subsequent reductive 
N−O bond cleavage (Figure 1B). This method appeared all the 
more appealing that the only example reported in the literature 
featuring the use of α-substituted isoxazolidin-5-ones was limited 
to the synthesis of α-sulfanyl-β2,2-amino acid derivatives 
via an enantioselective organocatalytic phase-transfer 
α-sulfanylation.[16] 
We thus initiated our study using 4-phenylisoxazolidin-5-one 
1a as a model substrate. The latter was prepared in four steps 
starting from diethyl malonate via a palladium-catalyzed 
arylation, a saponification, the formation of the corresponding 
C5-substituted Meldrum’s acids and a formal [3+2] 
cycloaddition.[17] This substrate was eventually engaged in a 
reactivity and enantioselectivity screen across an array of 
conditions; the results are summarized in Table 1. 
For the first set of conditions, we decided to evaluate the 
influence of the ligand by running the reactions in THF at room 
temperature using allyl acetate (1.0 equiv.), Na2CO3 (2.0 equiv.), 
Pd2(dba)3 (5 mol%) and a variety of chiral ligands (10 mol%). As 
a general trend, all the reactions afforded the corresponding 
α,α-disubstituted isoxazolidin-5-one in good yields ranging from 
85% to 95% independently of the ligand used. Interestingly 
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Table 1. Systematic study.a 
 
 
the selectivity. Indeed, the investigation revealed that phosphine 
oxazoline type ligands such as PHOX, (S)-L4, axially chiral 
diphosphines, such as BINAP, (R)-L5, spirocyclic diphosphines, 
such as (R)-SDP (L7), and the phosphoramidite-type ligands 
such as (S,R,R)-L6 induced low levels of enantioselectivity 
(Table 1, entries 4-7), while the C2-symmetric diphosphines 
developed by Trost et al. (L1, L2 and L3) afforded much higher 
ees ranging from 26% to 90%; the best results being obtained 
with L1 (Table 1, entry 1). 
With this result in hand, we next evaluated the influence of 
the base, which appeared to have a limited impact on the 
selectivity as exemplified by the ees obtained with Na2CO3 
(90% ee, Table 1, entry 1), Li2CO3 (87% ee, Table 1, entry 8), 
Cs2CO3 (82% ee, Table 1, entry 9), NaH (87% ee, Table 1 entry 
10) and DBU (86% ee, Table 1, entry 11). However, while most 
bases afforded the allylated product in good to excellent yields 
(82-95%), the use of DBU was detrimental as the yield 
drastically decreased to 14%. 
To optimize this Pd-AAA reaction further, we also evaluated 
the influence of the palladium catalyst precursor and found 
Pd2(dba)3  (95% yield, 90% ee) to be superior to [Pd(allyl)Cl]2 
(43% yield, 70% ee), [Pd(cinnammyl)(Cl)]2 (40% yield, 80% ee) 
and Pd(OAc)2 (10% yield, 78% ee) (not shown in Table; 
see Supporting Information for more details). In addition, 
decreasing the amount of Pd2(dba)3 from 5 to 1.25 mol% led to a 
considerable erosion of the ee from 90% to 79% and this option 
was therefore discarded. 
We next wondered whether a change in the 
enantionselectivity would be observed if running the Pd-AAA 
process along with some additives under otherwise identical 
conditions. However, a complete shutdown of the reaction was 
observed when stoichiometric amounts of LiCl were used, while 
the use of 15-crown-5 provided comparable enantioselectivities 
albeit lower yields. 
We eventually investigated the effect of the solvent on the 
selectivity outcome. As a general trend, ethers such as THF 
(Table 1, entry 1), MTBE (Table 1, entry 12) and dioxane 
(Table 1, entry 13), and more polar solvents such as NMP 
(Table 1,entry 16) provided the best selectivities with ees 
ranging from 82 to 90%. Curiously, the use of solvents such as 
toluene (Table 1, entry 14) and MeCN (Table 1, entry 15) 
afforded the alkylated product in quasi-quantitative yield, 
however in a much lower enantioselectivity (66% and 42% ee 
respectively). Finally, the ees could be slightly improved by 
running the reaction at a lower temperature such as 0 °C or 
−10 °C (Table 1, entries 17 and 18), however, for practical 
purposes we decided to set the reaction temperature at 0 °C. 
After having identified the best set of reaction conditions 
[Pd2(dba)3 (5 mol%), (R,R)-L1 (10 mol%), Na2CO3 (2 equiv), 
THF, 0 °C], we next examined the substrate scope by applying 
these conditions to various 4-substituted isoxazolidin-5-ones. 
The results are summarized in Table 2. 
 
Table 2. Scope of the Pd-AAA of 4-substituted isoxazolidin-5-ones.a 
 
 
As a general trend, this method proved to be applicable to a 
wide range of 4-aryl/heteroaryl isoxazolin-5-ones as illustrated 
by the high yields (86-97%) and the excellent enantioselectivities 





aUnless otherwise noted, all reactions were run on a  0.19 mmol scale using 5 mol% of Pd2(dba)3 and 10 
mol% of ligand. bIsolated yield. cDetermined by Supercritical Fluid Chromatography (SFC) analysis. d5 
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aUnless otherwise noted, all reactions were run on a  0.19 mmol scale using 5 mol% of Pd2(dba)3 and 
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donating substituent on the arene ring, such as a p-methoxy 
(86% yield, 87% ee) or a p-methyl (91% yield, 90% ee), as well 
as compounds bearing an electron-withdrawing substituent on 
the arene ring, such as a p-chloro (92% yield, 91% ee), a 
p-bromo (91% yield, 89% ee), a p-fluoro (97% yield, 92% ee) or 
a p-trifluoromethyl (92% yield, 91% ee), appeared to be suitable. 
In addition, the optical purity of the products could be further 
improved after recrystallization from a pentane/ether mixture. 
This was the case for the crystalline product 2a which was 
isolated in a quasi enantiopure form (>99% ee). 
As for the absolute configuration of the newly formed all-
carbon quaternary stereogenic center, it could be predicted 
using the model proposed by Trost et al. where the enolate 
approaches the π-allylpalladium-(R,R)-L1 complex by its Re 
face to avoid any disfavored steric interaction between the “wall” 
of the ligand and the Boc group of the substrate. This selectivity 
was later confirmed by single crystal X-Ray analysis 
(see structure in Table 2). 
In an effort to broaden the scope of the reaction, we 
subsequently turned our attention to introduce more structural 
diversity using substituted allyl acetates, in particular 
2-substituted allyl acetates. The results are depicted in Table 3.  
 
Table 3. Scope of the Pd-AAA with 2-substituted allyl acetates.a 
 
 
Interestingly, when subjecting isoxazolidin-5-one 1a to an 
array of allyl acetates under the aforementioned conditions we 
were able to isolate the corresponding α-allylated products in 
generally excellent enantioselectivities (up to 95% ee). Overall, 
electronic effects appeared to have a much more pronounced 
impact on the enantioselectivity than steric effects. Indeed, 
increasing the bulk of the substituent at the C2 position by 
replacing the hydrogen atom (2a, 91% ee) with a methyl (2i, 
95% ee), a trimethylsilyl (2j, 93% ee) or a phenyl (2m, 95% ee) 
led to a slight improvement of the enantioselectivity albeit along 
with a small loss of reactivity. In contrast, replacing the hydrogen 
with a chlorine atom (2m, 74% ee) or a methylester (2n, 
25% ee) had a detrimental effect on both the enantioselectivity 
and the yield. Interestingly, the use of 2-[(trimethylsilyl)methyl] 
allyl acetate yielded the methallyl derivative 2j in 94% yield and 
90% ee. Finally, a complete shut down of the reaction was even 
observed when using a 2-methoxy-substituted allyl acetate (2o). 
Finally, after having established a practical and highly 
enantioselective route to enantioenriched α,α-disubstituted 
isoxazolidin-5-ones 2, we decided to demonstrate the synthetic 
utility of the method by developing a straightforward sequence 
which would allow to convert the latter to the corresponding 
β2,2-amino acids 3 and β-lactams 4 (Scheme 1). 
 
 
Scheme 1. Synthesis of β2,2-amino acids and β-lactams. 
To effect the N-O bond cleavage, we screened various 
reaction conditions (Na2S2O4/EtOH/H2O, SmI2/THF, 
Zn/AcOH),[18] however none of them led the desired amino acid. 
Luckily, the use of sodium naphthalenide in THF at −78 °C 
afforded the title product 3 in 90% isolated yield. Subsequent 
methylation of the carboxylic acid using TMSCHN2, Boc-
deprotection using TFA and lactam formation using Et3N, TMSCl 
followed by t-BuMgCl resulted in the formation of the 
corresponding cyclized product 4, which was N-Boc protected 
for purification purposes.[19] 
In summary, we have developed a novel, robust and highly 
enantioselective catalytic protocol for the synthesis of 
α,α-disubstituted isoxazolidin-5-ones bearing an all-carbon 
α-quaternary stereogenic center.[20] The method relies on a key 
palladium-catalyzed asymmetric allylic alkylation and affords the 
desired products in both high yields and excellent 
enantioselectivities (ees up to 95%). Besides the high level of 
efficiency and stereocontrol achieved, this method allows a 
straightforward entry into the valuable β2,2-amino acids and 
β-lactams. 
Experimental Section 
General procedure for the Pd-AAA with allyl acetate: To a solution of 
Pd2(dba)3 (0.01 mmol, 0.05 equiv) in THF (1 mL) at rt was added 
(R,R)-L1 (0.02 mmol, 0.1 equiv) and the mixture was stirred for 30 min. 
This solution was then cooled to 0 °C and transferred via cannula to a 
flask containing a cooled solution (0 °C) of 4-substituted isoxazolidin-5-
one (0.19 mmol, 1.0 equiv) and Na2CO3 (0.38 mmol, 2.0 equiv) in THF 
(1 mL). Once the addition was complete, allyl acetate (0.19 mmol, 
1.0 equiv) was added and the reaction mixture was stirred at the same 
temperature until complete consumption of the starting material (reaction 
monitored by TLC). The reaction mixture was eventually filtered through 
a plug of Celite© and concentrated under reduced pressure to afford a 
crude residue, which was purified by flash column chromatography over 
silica gel. 
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aUnless otherwise noted, all reactions were run on a  0.19 mmol scale using 5 mol% of Pd2(dba)3 and 





























































2) TFA, CH2Cl2, 0 °C
3) Et3N, TMSCl then t-BuMgCl
1) TMSCHN2, toluene/MeOH, 0 °C
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AAA for AA. An unprecedented and highly enantioselective palladium-catalyzed 
allylic alkylation of 4-substituted isoxazolidin-5-ones is reported. The method is both 
high yielding and highly enantioselective, and allows a straightforward access to 
β2,2-amino acids and β-lactams bearing an all-carbon α-quaternary stereogenic 
center. 
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